Prot # B3461028: Tafamidis: A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison

Project: Research project

Project Details

Effective start/end date1/22/141/21/20


  • ICON Clinical Research, LLC (Prot # B3461028 // Prot # B3461028)
  • Pfizer Inc. (Prot # B3461028 // Prot # B3461028)